Research graph
References from Primary Cutaneous Lymphomas and Lymphoproliferative Disorders: Current Insights for Classification and Management. Local targets link to admitted publications; unresolved targets remain external evidence.
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders
10.1093/bjd/ljaf312 · 2025 · External reference
The fifth edition of the WHO-Classification—What is new for cutaneous lymphomas?
2024 · External reference
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
10.1182/blood-2018-11-881268 · 2019 · External reference
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee
10.1182/blood.2022015851 · 2022 · External reference
Unresolved reference
External reference
Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26760 · 2023 · External reference
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—Update 2023
10.1016/j.ejca.2023.113343 · 2023 · External reference
Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26968 · 2023 · External reference
Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group
10.1111/jdv.19987 · 2024 · External reference
Primary cutaneous follicle center cell lymphomas and large B cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis
10.1046/j.0022-202x.2001.01543.x · 2001 · External reference
Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling
10.1182/blood-2004-04-1594 · 2005 · External reference
Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas
10.1111/1523-1747.ep12371768 · 1994 · External reference
Primary cutaneous follicle center cell lymphoma with follicular growth pattern
10.1182/blood.v95.12.3922 · 2000 · External reference
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas
10.1038/s41379-018-0041-7 · 2018 · External reference
Recent advances in cutaneous lymphoma-implications for current and future classifications
10.1007/s00428-022-03421-5 · 2023 · External reference
Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment
10.1016/j.jid.2022.07.027 · 2023 · External reference
Updated Classification of Cutaneous Lymphoma
10.1097/pap.0000000000000487 · 2025 · External reference
Unresolved reference
External reference
Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: The BC Cancer Agency experience
10.1016/j.ijrobp.2013.07.019 · 2013 · External reference
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: Report and follow-up of eight cases
10.1111/j.1365-2133.2006.07523.x · 2006 · External reference
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod
10.1111/j.1365-2133.2007.07976.x · 2007 · External reference
Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma
10.1111/j.1365-2133.2012.10902.x · 2012 · External reference
New insights into folliculotropic mycosis fungoides (FMF): A single-center experience
10.1016/j.jaad.2016.03.009 · 2016 · External reference
10.3390/cancers13081931
10.3390/cancers13081931 · External reference
Granulomatous mycosis fungoides and granulomatous slack skin: A multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC)
10.1001/archdermatol.2008.46 · 2008 · External reference
Genetic and epigenetic insights into cutaneous T-cell lymphoma
10.1182/blood.2019004256 · 2022 · External reference
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome
10.1038/ng.3442 · 2015 · External reference
ALK-positive anaplastic large cell lymphoma limited to the skin: Clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study
10.3324/haematol.2012.065664 · 2013 · External reference
ALK-positive primary cutaneous anaplastic large cell lymphoma: A case report and review of the literature
10.1111/ijd.13804 · 2018 · External reference
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features
10.1111/jdv.16969 · 2021 · External reference
Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group
10.1097/pas.0000000000001470 · 2020 · External reference
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: Results of an EORTC Cutaneous Lymphoma Group workshop
10.1111/bjd.20973 · 2022 · External reference
Response to topical corticosteroid monotherapy in mycosis fungoides
10.1016/j.jaad.2020.05.043 · 2021 · External reference
Treatment of patch-stage mycosis fungoides with topical corticosteroids
10.1111/j.1396-0296.2003.01639.x · 2003 · External reference
Narrowband UVB and PUVA in the treatment of mycosis fungoides: A retrospective study
10.2340/00015555-0283 · 2007 · External reference
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: An EORTC CLTG study
10.1093/bjd/ljae152 · 2024 · External reference
Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: A retrospective cohort study
10.1093/bjd/ljag073 · 2026 · External reference
Methotrexate in mycosis fungoides revisited
10.1111/jdv.20789 · 2025 · External reference
10.3390/cancers18010097
10.3390/cancers18010097 · External reference
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
10.2147/dddt.s185896 · 2020 · External reference
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
10.1016/s2352-3026(25)00228-5 · 2025 · External reference
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
10.1182/blood-2007-03-055749 · 2007 · External reference
Topical Corticosteroids for Mycosis Fungoides
10.1001/archderm.134.8.949 · 1998 · External reference
Topical chemotherapy in cutaneous T-cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides
10.1001/2013.jamadermatol.541 · 2013 · External reference
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
2001 · External reference
Topical carmustine (BCNU) for mycosis fungoides and related disorders: A 10-year experience
10.1016/s0190-9622(83)70143-x · 1983 · External reference
Topical imiquimod as treatment for different kinds of cutaneous lymphoma
2006 · External reference
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
10.1182/blood-2015-02-630335 · 2015 · External reference
Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium
10.1016/j.jaad.2015.09.033 · 2016 · External reference
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China
10.1016/j.ijrobp.2015.08.012 · 2015 · External reference
Revisiting low-dose total skin electron beam therapy in mycosis fungoides
10.1016/j.ijrobp.2011.01.023 · 2011 · External reference
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
10.1200/jco.2001.19.9.2456 · 2001 · External reference
Guidelines on the use of extracorporeal photopheresis
10.1111/jdv.12311 · 2014 · External reference
Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3 trial
10.1016/s0140-6736(17)31266-7 · 2017 · External reference
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
10.1200/jco-24-01549 · 2025 · External reference
Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: A multicenter phase II study
10.1200/jco.19.01056 · 2020 · External reference
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): A propensity score matched controlled prospective study
10.1016/s0140-6736(23)00329-x · 2023 · External reference
Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
10.1111/ijd.17352 · 2025 · External reference
When Ice Hurts
10.1016/j.ijrobp.2023.08.040 · 2023 · External reference
10.3390/cancers18101560
10.3390/cancers18101560 · External reference
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · 2017 · External reference
Topical chemotherapy in cutaneous T-cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides
10.1001/2013.jamadermatol.541 · ExternalCitation · doi-reference
Topical Corticosteroids for Mycosis Fungoides
10.1001/archderm.134.8.949 · ExternalCitation · doi-reference
Granulomatous mycosis fungoides and granulomatous slack skin: A multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC)
10.1001/archdermatol.2008.46 · ExternalCitation · doi-reference
Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26760 · ExternalCitation · doi-reference
Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26968 · ExternalCitation · doi-reference
Recent advances in cutaneous lymphoma-implications for current and future classifications
10.1007/s00428-022-03421-5 · ExternalCitation · doi-reference
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—Update 2023
10.1016/j.ejca.2023.113343 · ExternalCitation · doi-reference
Revisiting low-dose total skin electron beam therapy in mycosis fungoides
10.1016/j.ijrobp.2011.01.023 · ExternalCitation · doi-reference
Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: The BC Cancer Agency experience
10.1016/j.ijrobp.2013.07.019 · ExternalCitation · doi-reference
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China
10.1016/j.ijrobp.2015.08.012 · ExternalCitation · doi-reference
When Ice Hurts
10.1016/j.ijrobp.2023.08.040 · ExternalCitation · doi-reference
Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium
10.1016/j.jaad.2015.09.033 · ExternalCitation · doi-reference
New insights into folliculotropic mycosis fungoides (FMF): A single-center experience
10.1016/j.jaad.2016.03.009 · ExternalCitation · doi-reference
Response to topical corticosteroid monotherapy in mycosis fungoides
10.1016/j.jaad.2020.05.043 · ExternalCitation · doi-reference
Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment
10.1016/j.jid.2022.07.027 · ExternalCitation · doi-reference
Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3 trial
10.1016/s0140-6736(17)31266-7 · ExternalCitation · doi-reference
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): A propensity score matched controlled prospective study
10.1016/s0140-6736(23)00329-x · ExternalCitation · doi-reference
Topical carmustine (BCNU) for mycosis fungoides and related disorders: A 10-year experience
10.1016/s0190-9622(83)70143-x · ExternalCitation · doi-reference
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
10.1016/s2352-3026(25)00228-5 · ExternalCitation · doi-reference
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · ExternalCitation · doi-reference
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome
10.1038/ng.3442 · ExternalCitation · doi-reference
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
10.1038/s41375-022-01620-2 · ExternalCitation · doi-reference
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas
10.1038/s41379-018-0041-7 · ExternalCitation · doi-reference
Primary cutaneous follicle center cell lymphomas and large B cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis
10.1046/j.0022-202x.2001.01543.x · ExternalCitation · doi-reference
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: An EORTC CLTG study
10.1093/bjd/ljae152 · ExternalCitation · doi-reference
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders
10.1093/bjd/ljaf312 · ExternalCitation · doi-reference
Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: A retrospective cohort study
10.1093/bjd/ljag073 · ExternalCitation · doi-reference
Updated Classification of Cutaneous Lymphoma
10.1097/pap.0000000000000487 · ExternalCitation · doi-reference
Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group
10.1097/pas.0000000000001470 · ExternalCitation · doi-reference
Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas
10.1111/1523-1747.ep12371768 · ExternalCitation · doi-reference
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: Results of an EORTC Cutaneous Lymphoma Group workshop
10.1111/bjd.20973 · ExternalCitation · doi-reference
ALK-positive primary cutaneous anaplastic large cell lymphoma: A case report and review of the literature
10.1111/ijd.13804 · ExternalCitation · doi-reference
Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
10.1111/ijd.17352 · ExternalCitation · doi-reference
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: Report and follow-up of eight cases
10.1111/j.1365-2133.2006.07523.x · ExternalCitation · doi-reference
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod
10.1111/j.1365-2133.2007.07976.x · ExternalCitation · doi-reference
Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma
10.1111/j.1365-2133.2012.10902.x · ExternalCitation · doi-reference
Treatment of patch-stage mycosis fungoides with topical corticosteroids
10.1111/j.1396-0296.2003.01639.x · ExternalCitation · doi-reference
Guidelines on the use of extracorporeal photopheresis
10.1111/jdv.12311 · ExternalCitation · doi-reference
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features
10.1111/jdv.16969 · ExternalCitation · doi-reference
Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group
10.1111/jdv.19987 · ExternalCitation · doi-reference
Methotrexate in mycosis fungoides revisited
10.1111/jdv.20789 · ExternalCitation · doi-reference
Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling
10.1182/blood-2004-04-1594 · ExternalCitation · doi-reference
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
10.1182/blood-2007-03-055749 · ExternalCitation · doi-reference
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
10.1182/blood-2015-02-630335 · ExternalCitation · doi-reference
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
10.1182/blood-2018-11-881268 · ExternalCitation · doi-reference
Genetic and epigenetic insights into cutaneous T-cell lymphoma
10.1182/blood.2019004256 · ExternalCitation · doi-reference
The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee
10.1182/blood.2022015851 · ExternalCitation · doi-reference
Primary cutaneous follicle center cell lymphoma with follicular growth pattern
10.1182/blood.v95.12.3922 · ExternalCitation · doi-reference
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
10.1200/jco-24-01549 · ExternalCitation · doi-reference
Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: A multicenter phase II study
10.1200/jco.19.01056 · ExternalCitation · doi-reference
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
10.1200/jco.2001.19.9.2456 · ExternalCitation · doi-reference
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
10.2147/dddt.s185896 · ExternalCitation · doi-reference
Narrowband UVB and PUVA in the treatment of mycosis fungoides: A retrospective study
10.2340/00015555-0283 · ExternalCitation · doi-reference
ALK-positive anaplastic large cell lymphoma limited to the skin: Clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study
10.3324/haematol.2012.065664 · ExternalCitation · doi-reference
10.3390/cancers13081931
10.3390/cancers13081931 · ExternalCitation · doi-reference
10.3390/cancers18010097
10.3390/cancers18010097 · ExternalCitation · doi-reference
10.3390/cancers18101560
10.3390/cancers18101560 · ExternalCitation · doi-reference
